Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc., as noted in the metadata) on October 13, 2021, covering events occurring on October 7, 2021. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of an interim replacement.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation adjustments.
Material Changes
- Departure of CFO: Clinton Musil resigned as Chief Financial Officer effective October 29, 2021, citing personal reasons.
- Interim Appointment: Seline Miller, previously the Controller, was promoted to Senior Vice President, Finance, and appointed as interim Chief Financial Officer and interim Principal Accounting Officer.
- Compensation Adjustment: In connection with her promotion, Mrs. Miller's annual base salary increased from $250,000 to $300,000, and her bonus target increased from 25% to 30%.
- Consulting Arrangement: Mr. Musil entered into a consulting agreement to provide services to the company following his departure.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the transition of financial leadership, though the company noted that Mr. Musil will provide consulting services during the transition period. No unusual items or contingencies were reported.
Investor Verification Checklist
- Verify the effective date of the CFO transition (October 29, 2021) and the duration of the interim arrangement.
- Review the full text of the Consulting Agreement (Exhibit 10.1) to understand the scope and terms of Mr. Musil's post-departure engagement.
- Confirm the timeline for the search and appointment of a permanent Chief Financial Officer.
- Check subsequent filings for any updates on the company's financial reporting status under the new interim leadership.